NEW YORK (GenomeWeb News) – Galapagos subsidiary BioFocus DPI will conduct drug discovery screening and targeting studies over a one-year period for Schering-Plough, Galapagos said today.

Under the €2.8 million ($4.1 million) agreement, BioFocus will perform medicinal chemistry and studies of absorption, distribution, excretion, and pharmacokinetics for multiple Schering-Plough projects at two sites in Europe.